Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

New data highlights an unprecedented crisis in National Health Service patient waiting lists and sheds light on how the ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.CEO Albert Bourla ...

Neuren Pharmaceutical's reports boosted sales of the Rett syndrome drug Daybue, but two-thirds of US patients are yet to try it.

In July, Seeking Alpha welcomed 44 new analysts. This article introduces them and showcases some of their top picks. Analysts ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...